Use of low-dosage erythropoietin for simulation of endothelial progenitor cells, for an organ regeneration and for slowing the progression of end-organ damage

ABSTRACT

The invention relates to the use of low-dose erythropoietin for simulating physical mobilization, proliferation, and differentiation of endothelial precursor cells, and producing pharmaceutical compositions used for the treatment of such diseases as well as pharmaceutical compositions containing erythropoietin and other appropriate agents for simulating endothelial precursor cells.

(No suitable figure)